EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Hydrochlorothiazide and increased risk of atypical fibroxanthoma and pleomorphic dermal sarcoma

Thomas Kuntz, Alexander Grimm, Silke C Hofmann iD, Alena-Lioba Michalowitz, Jörg Schaller, Martin Hellmich, Chalid Assaf, Frank Oellig, Alexander Kreuter iD

JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 2024

DOI: 10.1111/ddg.15379 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2024. Verfasst von Thomas Kuntz und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venereology, University of Cologne, Cologne, Germany. Hauptthemen laut MEDLINE: Skin Neoplasms, Histiocytoma, Malignant Fibrous, Sarcoma, Basal Cell Carcinoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives Previous work has demonstrated that hydrochlorothiazide (HCTZ) is a risk factor for squamous cell carcinomas (SCC) and basal cell carcinomas (BCC) due to pro‐photocarcinogenic effects. Atypical fibroxanthoma (AFX) and pleomorphic sarcoma (PDS), both ultraviolet‐induced cancers, display a rare but rising cutaneous tumor entity. This study aimed to evaluate if the use of HCTZ is higher in patients with AFX/PDS than in patients with SCC/BCC and subsequently may be a risk factor for AFX/PDS‐development. Patients and Methods In a retrospective study of four German skin cancer centers, AFX/PDS cases and SCC/BCC controls were sex and age matched (1:3) over a time‐period of 7 years (2013–2019) to evaluate the use of HCTZ, immunosuppressive medication, second malignancies, and presence of diabetes mellitus.

Results

Overall, 146 AFX/PDS and 438 controls (SCC/BCC) were included in the study. The use of HCTZ was significantly higher in patients with AFX/PDS (44.5%) compared to patients with SCC/BCC (25.3%). Additionally, the presence of diabetes mellitus was significantly higher in AFX/PDS patients.

Conclusions

This study demonstrates a significantly higher use of HCTZ in patients with AFX/PDS compared to SCC/BCC. This result suggests that HCTZ may be a risk factor for AFX/PDS. Additionally, diabetes mellitus or its comorbidities may be associated with an increased risk for AFX/PDS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Skin NeoplasmsHistiocytoma, Malignant FibrousSarcomaBasal Cell CarcinomaCarcinoma, Squamous CellDiabetes MellitusHumansHydrochlorothiazideRetrospective Studies

Stichwörter der Autor:innen

Atypical fibroxanthomacutaneous sarcomahydrochlorothiazidepleomorphic dermal sarcomaspindle‐cell tumors

Substanzen

Hydrochlorothiazide

Autor:innen und Institutionen

  • Department of Dermatology and Venereology, University of Cologne, Cologne, Germany.
  • Department of Dermatology, Venereology, and Allergology, Helios St. Elisabeth Hospital Oberhausen, University of Witten-Herdecke, Oberhausen, Germany.
  • Department of Dermatology, Allergology, und Dermatosurgery, Helios University Hospital Wuppertal, University of Witten-Herdecke, Wuppertal, Germany.
  • Department of Dermatology, Venereology, and Allergology, Helios St. Johannes Hospital Duisburg, Duisburg, Germany.
  • Institute of Medical Statistics and Computational Biology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Department of Dermatology and Venereology, Helios Klinikum Krefeld, Krefeld, Germany.

ORCID-Profile: Silke C Hofmann, Alexander Kreuter

Zitieren

APA

Kuntz, T., Grimm, A., Hofmann, S. C., Michalowitz, A. L., Schaller, J., Hellmich, M., Assaf, C., Oellig, F., & Kreuter, A. (2024). Hydrochlorothiazide and increased risk of atypical fibroxanthoma and pleomorphic dermal sarcoma. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. https://doi.org/10.1111/ddg.15379

Vancouver

Kuntz T, Grimm A, Hofmann SC, Michalowitz AL, Schaller J, Hellmich M, et al. Hydrochlorothiazide and increased risk of atypical fibroxanthoma and pleomorphic dermal sarcoma. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2024. doi:10.1111/ddg.15379

BibTeX
@article{Kuntz2024,
  author = {Kuntz, Thomas and Grimm, Alexander and Hofmann, Silke C and Michalowitz, Alena-Lioba and Schaller, Jörg and Hellmich, Martin and Assaf, Chalid and Oellig, Frank and Kreuter, Alexander},
  title = {Hydrochlorothiazide and increased risk of atypical fibroxanthoma and pleomorphic dermal sarcoma},
  journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
  year = {2024},
  doi = {10.1111/ddg.15379}
}
Kostenlos starten →